# Efficacy and Safety of PR022 Topical Gel to Treat Mild-to-Moderate Atopic Dermatitis

> **NCT03351777** · PHASE2 · UNKNOWN · sponsor: **Realm Therapeutics, Inc.** · enrollment: 120 (estimated)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** PR022

## Key facts

- **NCT ID:** NCT03351777
- **Lead sponsor:** Realm Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-12-04
- **Primary completion:** 2018-04
- **Final completion:** 2018-07
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2017-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03351777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03351777, "Efficacy and Safety of PR022 Topical Gel to Treat Mild-to-Moderate Atopic Dermatitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03351777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*